ArticleThe Journal of clinical investigation2002
Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model.
Article in The Journal of clinical investigation, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 105 citations in OpenAlex.
- Immunoproteasome inhibition attenuates experimental psoriasis.Frontiers in immunology · 2022Article
- Coagulopathies after Vaccination against SARS-CoV-2 May Be Derived from a Combined Effect of SARS-CoV-2 Spike Protein and Adenovirus Vector-Triggered Signaling Pathways.International journal of molecular sciences · 2021Review
- Bortezomib: a proteasome inhibitor for the treatment of autoimmune diseases.Inflammopharmacology · 2021Review
- Translational Clinical Strategies for the Prevention of Gastrointestinal Tract GraftFrontiers in immunology · 2021Review
- Reduced Proteasome Activity and Enhanced Autophagy in Blood Cells of Psoriatic Patients.International journal of molecular sciences · 2020Article
- Changes in Proteome of Fibroblasts Isolated from Psoriatic Skin Lesions.International journal of molecular sciences · 2020Article
- Lactacystin: first-in-class proteasome inhibitor still excelling and an exemplar for future antibiotic research.The Journal of antibiotics · 2019Review
- Inhibition of Proteasome Activity by Low-dose Bortezomib Attenuates Angiotensin II-induced Abdominal Aortic Aneurysm in Apo E(-/-) Mice.Scientific reports · 2015Article
- Proteasome inhibitor bortezomib suppresses nuclear factor-kappa B activation and ameliorates eye inflammation in experimental autoimmune uveitis.Mediators of inflammation · 2015Article
- Proteasome inhibitors act as bifunctional antagonists of human immunodeficiency virus type 1 latency and replication.Retrovirology · 2013Article
- Proteasome inhibition alleviates prolonged moderate compression-induced muscle pathology.BMC musculoskeletal disorders · 2011Article
- High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases.Clinical reviews in allergy & immunology · 2010Review
- Junctional adhesion molecule (JAM)-B supports lymphocyte rolling and adhesion through interaction with alpha4beta1 integrin.Immunology · 2009Article
- Comparison of human fetal liver, umbilical cord blood, and adult blood hematopoietic stem cell engraftment in NOD-scid/gammac-/-, Balb/c-Rag1-/-gammac-/-, and C.B-17-scid/bg immunodeficient mice.Human immunology · 2009Article
- Article
- Strong associations of psoriasis with antigen processing LMP and transport genes TAP differ by gender and phenotype.Genes and immunity · 2007Article
- Proteasome inhibitors: antitumor effects and beyond.Leukemia · 2007Review
- Proteasomal chymotrypsin-like peptidase activity is required for essential functions of human monocyte-derived dendritic cells.Immunology · 2007Article
- [Psoriasis SCID-mouse model].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2006Review
- Humanized mice: are we there yet?The Journal of experimental medicine · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is increasing evidence that bacterial superantigens contribute to inflammation and T cell responses in psoriasis. Psoriatic inflammation entails a complex series of inductive and effector processes that require the regulated expression of various proinflammatory genes, many of which require NF-kappa B for maximal trans-activation. PS-519 is a potent and selective proteasome inhibitor based upon the naturally occurring compound lactacystin, which inhibits NF-kappa B activation by blocking the degradation of its inhibitory protein I kappa B. We report that proteasome inhibition by PS-519 reduces superantigen-mediated T cell-activation in vitro and in vivo. Proliferation was inhibited along with the expression of very early (CD69), early (CD25), and late T cell (HLA-DR) activation molecules. Moreover, expression of E-selectin ligands relevant to dermal T cell homing was reduced, as was E-selectin binding in vitro. Finally, PS-519 proved to be therapeutically effective in a SCID-hu xenogeneic psoriasis transplantation model. We conclude that inhibition of the proteasome, e.g., by PS-519, is a promising means to treat T cell-mediated disorders such as psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.